Overview
- Reporting says that in April Eli Lilly provided retatrutide, an investigational Phase 3 obesity drug, to a single 79‑year‑old patient through the FDA’s Expanded Access (compassionate‑use) program for refractory obesity and related conditions.
- The patient’s identity remains undisclosed and the White House has denied that President Donald Trump was the recipient.
- Democrats moved the story into public view when Rep. Ted Lieu pressed the White House at a June 24 press event and Sen. Maggie Hassan sent a letter to HHS Secretary Robert F. Kennedy Jr. seeking who approved the request and what communications took place.
- Medical ethicists and clinicians call single‑patient access for an obesity indication unusual because obesity is widespread and approved weight‑loss drugs are already available, and reporting says the request was filed by an NIH clinician and drew interest from senior health officials.
- Eli Lilly, the FDA and HHS have offered limited public detail about the case so far, and lawmakers are likely to press for records, agency explanations and clearer limits on expanded access to prevent preferential treatment.